Forgot Password?
Return to Course Listing

CME: Optimizing care in advanced non-small cell lung cancer (NSCLC): Zeroing in on personalized medicine with precision


Activity Description / Statement of Need:

In this online, self-learning activity:

Lung cancer is the leading cause of cancer-related death in the United States with over 235,000 new cases diagnosed and representing a quarter of all cancer deaths at a rate of 132,000 annually. While smoking contributes to 82% of lung cancer deaths, nonsmoking-related lung cancer deaths still fall in the top ten causes of cancer deaths and represents a growing proportion of cases. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer diagnosed, accounting for approximately 80% of patients diagnosed. Despite clear guidance on surveillance for disease in individuals at high risk, late diagnosis is a fundamental obstacle to improving lung cancer outcomes. 55% of NSCLC cases are diagnosed after metastasis, at which point the two- and five-year survival rates are 20% and 6.1%, respectively, whereas patients diagnosed with local disease experience survival rates of 81% and 61.4%, respectively. Treatment decisions are influenced by disease stage, histology (squamous vs. non-), and the tumor’s molecular features (e.g., PD-L1, EGFR, ALK, BRAF, NTRK, ROS1), although patient factors like performance status and comorbidities should also inform the development, optimization, and personalizing of individual treatment plans. First-line therapy for patients with advanced-stage NSCLC who are anti-programmed-death 1 (PD-1) positive is immunotherapy with a targeted monoclonal antibody. Targeted therapies are also preferred over platinum-based doublets as first-line therapy in patients whose tumors have targetable genetic mutations. The care plan need take into account management of adverse events from therapy, which may result in treatment delays, increased morbidity, or contribute to treatment failure.

Target Audience:

HCPs specializing in: Oncology, pulmonology, and pathology; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with advanced NSCLC.

Commercial Support Disclosure: This program is supported by educational grants from Amgen, Bayer, and Novocure.

This activity is free of charge.

Release Date: August 05, 2022 -- Expiration Date: August 05, 2023

Faculty: Erminia Massarelli, M.D., Ph.D., MS


Faculty introduction, disclosures

Introductory content in advanced NSCLC

  • Epidemiology: Statistics by severity
  • Histopathology, oncogenesis, mutation status, biomarker testing, and prognosis

Updates in treatment in patients with advanced NSCLC

  • Present and emerging therapy, including goals of therapy and recent clinical trial summary
  • Standards of care and first-line treatment
  • Therapy targets: NTRK fusion; ALK, ROS1, RET rearrangements; EGFR, BRAF mutations; MET abnormalities

·       Gene mutations under investigation: HER2, HER3, Trop2, RAS/KRAS, BRCA

  • Therapy sequencing
  • Other areas of investigation: tumor treating fields
  • Clinical pearls: safety, tolerability, educating the patient (including managing treatment expectations), improving the provider-patient relationship, and those factors’ impact patient outcomes, including adherence to therapy
  • Patient cases

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Summarize the role of oncogenic drivers in pathogenesis of NSCLC.
  • Describe how biomarker testing guides the treatment of advanced NSCLC.
  • Recall present and emerging targeted therapies for advanced NSCLC.
  • Compose a treatment plan for a patient with advanced NSCLC and driver mutations.


ACCME Activity #202328650


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Faculty Disclosure: Erminia Massarelli, MD, PhD, MS, Associate Professor, Department of Medical Oncology, City of Hope,  has received financial compensation from AstraZeneca, Merck, Takeda, Lilly, Genentech, Janssen, Sanofi, BMS, and Daiichi Sankyo for consulting and/or speaker's bureau work.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will NOT discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by educational grants from Amgen, Bayer, and Novocure.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Novel and practical approaches to the prevention of neutropenia associated with myelosuppressive chemotherapy

Mesothelioma management Therapeutic updates and best practices

Biosimilars in the treatment of malignancies and supportive care

At the cutting edge of treatment for advanced diffuse large B-cell lymphoma (DLBCL): Updates in medical management and individualizing patient care